WO2017214190A1 - Cellules dendritiques modifiées exprimant la 1a-hydroxylase et utilisations associées pour le traitement de maladies à médiation immunitaire - Google Patents
Cellules dendritiques modifiées exprimant la 1a-hydroxylase et utilisations associées pour le traitement de maladies à médiation immunitaire Download PDFInfo
- Publication number
- WO2017214190A1 WO2017214190A1 PCT/US2017/036210 US2017036210W WO2017214190A1 WO 2017214190 A1 WO2017214190 A1 WO 2017214190A1 US 2017036210 W US2017036210 W US 2017036210W WO 2017214190 A1 WO2017214190 A1 WO 2017214190A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dendritic cell
- cells
- engineered
- engineered dendritic
- dcs
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 263
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 61
- 201000010099 disease Diseases 0.000 title claims abstract description 57
- 230000001404 mediated effect Effects 0.000 title claims abstract description 31
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 52
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 52
- 239000002157 polynucleotide Substances 0.000 claims abstract description 52
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 43
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 40
- 101000875403 Homo sapiens 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial Proteins 0.000 claims abstract description 28
- 102100036285 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial Human genes 0.000 claims abstract description 24
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 52
- 210000003289 regulatory T cell Anatomy 0.000 claims description 47
- 201000006417 multiple sclerosis Diseases 0.000 claims description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 33
- 208000016192 Demyelinating disease Diseases 0.000 claims description 20
- 102000006386 Myelin Proteins Human genes 0.000 claims description 20
- 108010083674 Myelin Proteins Proteins 0.000 claims description 20
- 210000005012 myelin Anatomy 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims description 14
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims description 14
- 230000001939 inductive effect Effects 0.000 claims description 12
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical group C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 210000001185 bone marrow Anatomy 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 235000021318 Calcifediol Nutrition 0.000 claims description 9
- 241000713880 Spleen focus-forming virus Species 0.000 claims description 9
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 claims description 8
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 claims description 8
- 230000001028 anti-proliverative effect Effects 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 229960004857 mitomycin Drugs 0.000 claims description 5
- 230000023105 myelination Effects 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 description 90
- 241001465754 Metazoa Species 0.000 description 46
- 229960005084 calcitriol Drugs 0.000 description 38
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 38
- 235000020964 calcitriol Nutrition 0.000 description 37
- 239000011612 calcitriol Substances 0.000 description 37
- 235000018102 proteins Nutrition 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 31
- 238000011282 treatment Methods 0.000 description 26
- 201000002491 encephalomyelitis Diseases 0.000 description 25
- 230000002163 immunogen Effects 0.000 description 21
- 210000003563 lymphoid tissue Anatomy 0.000 description 20
- 230000002093 peripheral effect Effects 0.000 description 20
- 230000003053 immunization Effects 0.000 description 19
- 238000002649 immunization Methods 0.000 description 17
- 230000002062 proliferating effect Effects 0.000 description 17
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- 102000003814 Interleukin-10 Human genes 0.000 description 15
- 108090000174 Interleukin-10 Proteins 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 229940076144 interleukin-10 Drugs 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 229930003316 Vitamin D Natural products 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 230000006698 induction Effects 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 235000019166 vitamin D Nutrition 0.000 description 14
- 239000011710 vitamin D Substances 0.000 description 14
- 150000003710 vitamin D derivatives Chemical class 0.000 description 14
- 229940046008 vitamin d Drugs 0.000 description 14
- 238000011740 C57BL/6 mouse Methods 0.000 description 13
- 102000004388 Interleukin-4 Human genes 0.000 description 13
- 108090000978 Interleukin-4 Proteins 0.000 description 13
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 13
- 238000000684 flow cytometry Methods 0.000 description 12
- 229940028885 interleukin-4 Drugs 0.000 description 12
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 11
- 238000010361 transduction Methods 0.000 description 11
- 230000026683 transduction Effects 0.000 description 11
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 10
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 10
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 102000047918 Myelin Basic Human genes 0.000 description 9
- 101710107068 Myelin basic protein Proteins 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000001186 cumulative effect Effects 0.000 description 8
- 230000003832 immune regulation Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000001769 paralizing effect Effects 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 7
- 230000007124 immune defense Effects 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 210000003007 myelin sheath Anatomy 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 210000004988 splenocyte Anatomy 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 230000009469 supplementation Effects 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 206010012305 Demyelination Diseases 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 241000713666 Lentivirus Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 5
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 5
- 102000003816 Interleukin-13 Human genes 0.000 description 5
- 108090000176 Interleukin-13 Proteins 0.000 description 5
- 108010002616 Interleukin-5 Proteins 0.000 description 5
- 102000000743 Interleukin-5 Human genes 0.000 description 5
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000003190 augmentative effect Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229940126585 therapeutic drug Drugs 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 4
- 102000000412 Annexin Human genes 0.000 description 4
- 108050008874 Annexin Proteins 0.000 description 4
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 4
- 230000033540 T cell apoptotic process Effects 0.000 description 4
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000008004 immune attack Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 3
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 description 3
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- -1 IL- 4 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000003416 augmentation Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000004957 immunoregulator effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000002602 induced regulatory T cell Anatomy 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000003076 paracrine Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 3
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000003614 tolerogenic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 2
- 208000018126 Adrenomyeloneuropathy Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
- 108010037842 Cytochrome P450 Family 27 Proteins 0.000 description 2
- 102000011109 Cytochrome P450 Family 27 Human genes 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 2
- 101001013648 Homo sapiens Methionine synthase Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 102000055324 Myelin Proteolipid Human genes 0.000 description 2
- 108700021862 Myelin Proteolipid Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 102000016202 Proteolipids Human genes 0.000 description 2
- 108010010974 Proteolipids Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 201000004339 autoimmune neuropathy Diseases 0.000 description 2
- 201000005011 autoimmune peripheral neuropathy Diseases 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000003094 enzyme-multiplied immunoassay technique Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 208000008795 neuromyelitis optica Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000010833 quantitative mass spectrometry Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 208000009174 transverse myelitis Diseases 0.000 description 2
- 102000009310 vitamin D receptors Human genes 0.000 description 2
- 108050000156 vitamin D receptors Proteins 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 241000714230 Avian leukemia virus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 108010061300 CXCR3 Receptors Proteins 0.000 description 1
- 102000011963 CXCR3 Receptors Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229940123150 Chelating agent Drugs 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102100024230 Dendritic cell-specific transmembrane protein Human genes 0.000 description 1
- 101710190014 Dendritic cell-specific transmembrane protein Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101100518992 Mus musculus Pax2 gene Proteins 0.000 description 1
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 102100037796 Zinc finger protein Helios Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 1
- 229960004361 calcifediol Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000182 cd11c+cd123- dc Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000010726 hind limb paralysis Diseases 0.000 description 1
- 102000048490 human CYP27B1 Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000001466 metabolic labeling Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 1
- 238000002028 two-dimensional gel electrophoresis-mass spectrometry Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
- C12Y114/13013—Calcidiol 1-monooxygenase (1.14.13.13), i.e. 25-hydroxyvitamin D-1-alpha-hydroxylase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
Definitions
- MS Multiple sclerosis
- CNS central nervous system
- Certain aspects of the present disclosure are generally directed to engineered cells and methods of treating immune-mediated diseases with minimal side effects on a patient's immune defense.
- a subset of immune cells is engineered to have a short life span and/or to synthesize de novo a therapeutic drug.
- the engineered cells can be dendritic cells.
- the engineered cells are dendritic cells that have been treated to inhibit or prevent cell proliferation.
- the therapeutic drug produced by the engineered cells has the ability to induce in the immune system another immune cell subset.
- the therapeutic drug can induce an immune cell subset that includes cells that have a long life span and/or the capacity to specifically suppress the immune attack without interfering with an individual's general immunity.
- the therapeutic drug can induce regulatory T cells.
- One aspect of the present disclosure is directed toward limiting the de novo synthesis of a high concentration of the therapeutic drug to the immune system, thereby preventing drug effects in other unintended tissues.
- the short life span of the engineered cells ensures that, upon induction of the long-lived but more specific regulatory cells (e.g., regulatory T cells), the drug is removed from the patient's body to ensure safety of the therapy.
- dendritic cells are engineered for de novo synthesis of a supra-physiological and/or therapeutic dose of the active vitamin D metabolite l,25[OH] 2 D, also referred to herein as calcitriol.
- the de novo synthesis of a therapeutic calcitriol dose is achieved through overexpression in dendritic cells of lct- hydroxylase that physiologically converts 25[OH]D (or calcidiol), the major vitamin D form in the blood circulation and the substrate for 1 ⁇ -hydroxylase, into calcitriol.
- the overexpression of 1 ⁇ -hydroxylase is achieved through transduction of dendritic cells with a vector that expresses cytochrome P450, family 27, subfamily B, polypeptide 1 (CYP27B1) gene.
- the CYP27Bl-engineered dendritic cells are loaded with one or more peptides (epitopes) that are specifically expressed in the diseased tissues and associated with pathogenesis of the disease.
- the epitope-loaded CYP27Bl-engineered dendritic cells (CYP27Bl-engineered DCs) are irradiated or treated to prevent further proliferation (non-proliferative).
- the epitope-loaded non-proliferative CYP27Bl-engineered DCs are intravenously injected into a mammal.
- the CYP27Bl-engineered DCs migrate into the peripheral lymphoid tissues.
- the CYP27Bl-engineered DCs can induce epitope-specific regulatory T cells which then specifically suppress pathogenic T cells.
- the pathogenic T cells can be the immune cells that are associated with pathogenesis of the immune-mediated disease.
- the accumulated epitope- specific regulatory T cells can specifically suppress pathogenic T cells.
- the accumulated epitope-specific regulatory T cells specifically promote apoptosis of pathogenic T cells.
- the CYP27Bl-engineered DCs spontaneously undergo apoptosis, thereby preventing prolonged generation of a high calcitriol concentration to avoid potential leaking into the systemic circulation and attending adverse side effects.
- vitamin D and/or 25[OH]D supplementation can be an adjuvant therapy to maintain a sufficient and same level of 25[OH]D in the blood circulation.
- the CYP27Bl-engineered DCs can be injected multiple times until the disease is completely controlled. In certain aspects, the time between the two injections can be at least two weeks.
- an engineered cell includes a dendritic cell that has been altered to overexpress a 1 ⁇ -hydroxylase.
- the dendritic cell has been altered by a transduction of the dendritic cell with a vector that expresses cytochrome P450 family 27 polypeptide 1.
- the transduction may be performed using a lentivirus or an FDA-approved virus.
- the dendritic cell is treated to achieve an inhibition of a proliferation of the dendritic cell.
- the dendritic cell may be treated with mitomycin C to achieve the inhibition of the proliferation of the dendritic cell.
- a method for treating an immune-mediated disease.
- the method includes: altering a dendritic cell so that the dendritic cell overexpresses a gene of cytochrome P450 family 27 polypeptide 1, thereby producing an engineered cell; treating the engineered cell so that a proliferation of the engineered cell is inhibited, thereby producing a non-proliferative engineered cell; and immunizing a patient having said immune-mediated disease with said non-proliferative engineered cell.
- immunizing comprises injecting into the patient having the immune-mediated disease an amount of the non-proliferative engineered cell that has been mixed with an epitope that is being targeted by the immune-mediated disease.
- engineered dendritic cells comprising a heterologous polynucleotide that encodes a lct-hydroxylase protein are provided.
- the engineered dendritic cell overexpresses the heterologous polynucleotide that encodes the 1 ⁇ -hydroxylase protein.
- the heterologous polynucleotide comprises a human cytochrome P450 family 27 subfamily B member 1 (CYP27B1) polynucleotide sequence.
- the heterologous polynucleotide is operably linked to a promoter.
- the promoter is a constitutively active promoter.
- the promoter is a spleen focus-forming virus (SFFV) promoter.
- the engineered dendritic cell comprises an expression cassette comprising a promoter operably linked to the heterologous polynucleotide that encodes the 1 ⁇ -hydroxylase protein.
- the engineered dendritic cell comprises a vector (e.g., a viral vector) that comprises an expression cassette comprising a promoter operably linked to the heterologous polynucleotide that encodes the 1 ⁇ - hydroxylase protein.
- the dendritic cell is a bone marrow-derived dendritic cell. In some embodiments, the dendritic cell is an activated dendritic cell.
- the engineered dendritic cell synthesizes 1,25- dihydroxyvitamin D at an increased level, relative to a control dendritic cell lacking the heterologous polynucleotide that encodes the 1 ⁇ -hydroxylase protein, when cultured in the presence of 25-hydroxyvitamin D.
- the engineered dendritic cell is pulsed with an antigen peptide.
- the antigen peptide is a peptide of a myelination protein.
- the antigen peptide is a peptide of myelin basic protein (MBP), proteolipid protein (PLP), or myelin oligodendrocyte glycoprotein (MOG), or a combination thereof.
- the engineered dendritic cell is treated with an anti- proliferative agent.
- the anti-proliferative agent is mitomycin C.
- compositions comprising a population of the engineered dendritic cell as described herein are provided.
- expression cassettes that comprises a promoter operably linked to a heterologous polynucleotide that encodes a lct-hydroxylase protein are provided.
- the expression cassette comprises a promoter (e.g., a constitutively active promoter, e.g., a spleen focus-forming virus (SFFV) promoter) that is operably linked to a polynucleotide comprising a human cytochrome P450 family 27 subfamily B member 1 (CYP27B1) polynucleotide sequence such as the polynucleotide sequence of NCBI GenBank Accession No. NM_000785.3.
- a promoter e.g., a constitutively active promoter, e.g., a spleen focus-forming virus (SFFV) promoter
- SFFV spleen focus-forming virus
- the expression cassette when introduced into a cell (e.g., a dendritic cell) results in the cell synthesizing 1,25-dihydroxyvitamin D at an increased level when cultured in the presence of 25-hydroxyvitamin D, relative to a control cell (e.g., control dendritic cell) lacking the expression cassette.
- vectors comprising the expression cassettes as described herein are provided.
- pharmaceutical compositions comprising an engineered dendritic cell or population of engineered dendritic cells as described herein and further comprising a pharmaceutically acceptable excipient are provided.
- the method comprises contacting one or more T cells with an engineered dendritic cell, composition comprising a population of engineered dendritic cells, or pharmaceutical composition as described herein.
- the T cells are myelin-specific T cells.
- methods of treating a subject having an immune-mediated disease comprising administering to the subject an engineered dendritic cell, composition comprising a population of engineered dendritic cells, or pharmaceutical composition as described herein.
- the immune-mediated disease is a demyelinating disease.
- the demyelinating disease is multiple sclerosis.
- FIG. 1A-1D Bone-marrow-derived dendritic cells
- BM-DCs bone-marrow-derived dendritic cells
- the BM-DCs were transduced with the lenti- CYP-GFP vector at days 4 and 6 during in vitro culture.
- Lentiviral vectors used in this study included lenti-CYP-GFP that carried a CYP27B1 gene and a GFP gene. SSFV and PGK were promoters.
- BM-DCs were transduced with no vector (Control), lenti-GFP (GFP), or lenti-CYP-GFP (hCYP27Bl). 48 hours after the last transduction, BM-DCs were then collected for analyzing expression of CYP27B1 mRNAs by real time PCR. To facilitate detection, CYP27B1 gene used in this study was human origin.
- D BM-DCs were cultured and transduced as shown in (C). 24 hours after the last transduction, the substrate 25[OH]D was added. The cells were cultured for another 24 hours and supernatants collected for measuring l,25(OH) 2 D concentration by a radioimmunoassay.
- FIG. 2A-2E lct-hydroxylase-overexpressing bone-marrow-derived maintain lymphoid tissue-homing capacity.
- A BM-DCs were generated and transduced for overexpression of lct-hydroxylase as described for FIG. 1. 24 hours after the last transduction, cells were analyzed for the expression of MHC I, MHC II, CD80, and CD86 by flow cytometry.
- B DC2.4 cells were transduced with lenti-CYP-GFP to generate a stable transfectant that constitutively overexpressed lct-hydroxylase and GFP ("DC2.4-CYP-GFP"). Subsequently, 1 x 10 6 DC2.4-CYP-GFP cells were subcutaneously injected into mice.
- FIG. 3A-3B One intravenous injection of immunogenic but non-proliferative BM- DCs overexpressing 1 ⁇ -hydroxylase and pulsed with MOG 35-55 suppresses ongoing experimental autoimmune encephalomyelitis.
- C57BL/6 mice were immunized with MOG 35-55 in Complete Freund Adjuvant for inducing experimental allergic encephalomyelitis (EAE).
- EAE experimental allergic encephalomyelitis
- EAE experimental allergic encephalomyelitis
- mDC2.4 Mean disease severity score for animals that received no treatment (No Tx) or that received 1 x 10 6 immunogenic but non-proliferative DC2.4 (mDC2.4).
- B Mean disease severity score for animals that received no treatment (No Tx) or that received 1 x 10 6 MOG 35-55 -pulsed immunogenic but nonproliferative DC2.4-CYP cells. Paralytic disease was monitored daily.
- FIG. 4A-4D 1 ⁇ -hydroxylase-overexpressing BM-DCs (bone-marrow-derived DCs) enhance apoptosis of CD4 + T cells in local draining lymph nodes.
- Animals were subcutaneously immunized with MOG 35-55 in Complete Freund Adjuvant (CFA).
- CFA Complete Freund Adjuvant
- animals subcutaneously received 1 x 10 s parental BM-DCs (DC) or BM-DCs that were transduced with lenti-CYP-GFP (DC-CYP).
- DC-CYP lenti-CYP-GFP
- mononuclear cells from local draining lymph nodes were examined for Annexin and PI staining in different T cell subsets by flow cytometry.
- A Experimental design.
- B Gating strategy.
- C Representative FACS plots showing Annexin and PI staining in all, CD4 + and CD8 + T cells.
- D Cumulative data showing the percentage of apoptotic cells among CD4 + T cells (left panel) and among CD8 + T cells (right panel). *P ⁇ 0.05.
- FIG. 5A-5D 1 ⁇ -hydroxylase-overexpressing BM-DCs create in the peripheral lymphoid tissues a microenvironment that favors differentiation of IL-10 + Treg and Th2 cells.
- CFA Complete Freund Adjuvant
- C Representative plots (upper panel) and cumulative data (lower panels) showing the percentages of IL-2 + and IL-10 + CD4 + T cells.
- D Representative plots (upper panels) and cumulative data (lower panels) showing the percentages of IL-4 + , IL-5 + , IL6 + , and IL-13 + CD4 + T cells. *P ⁇ 0.05.
- FIG. 6 lct-hydroxylase-overexpressing BM-DCs increase secretion of IL-2, IL-10, IL- 4, and IL-6 in splenocytes.
- CFA Complete Freund Adjuvant
- splenocytes from the animals were stimulated with MOG 35-55 -pulsed DCs and 48 hours later supernatants collected for analyzing secretion of IL- 2 (upper left panel), IL-10 (upper right panel), IL-4 (lower left panel), and IL-6 (lower right panel) by flow cytometry. *P ⁇ 0.05.
- FIG. 7A-7E DC-CYP stimulates the expression of Th2 and Trl cytokines in CD4 + T cells.
- A Experimental schematic. C57BL/6 mice were subcutaneously immunized with MOG35..55 emulsified in Complete Freund Adjuvant (CFA). At days 10, 17, and 24, the animals subcutaneously received one of the following immunizations ("immu"): (1) no immunization (No immu); or (2) 1 x 10 6 DC-mCYP-GFP. Nine days after the final immunization, splenocytes from the animals were stimulated with MOG 35-55 -pulsed DC2.4.
- CFA Complete Freund Adjuvant
- FIG. 8A-8C DC-CYP stimulates foxp3 + Treg cells in the peripheral lymphoid tissues.
- Immu immunizations
- B Representative FACS plots show foxp3 + cells among CD3 + T cells.
- FIG. 9A-9C Immunization with MOG 35-55 -pulsed DC-CYP but not parental DCs suppresses ongoing EAE.
- C57BL/6 mice were immunized with MOG 35-55 for the induction of EAE. Ten days later, the animals intravenously received one of the following immunizations ("Immu"): (1) no immunizations ("No immu”); (2) 1 x 10 6 DC2.4-mCYP-GFP; or (3) 1 x 10 6 MOG 3 5 -S s-pulsed (100 ⁇ for 3 hours) DC2.4-mCYP-GFP. The animals were then monitored for paralytic symptoms daily. At day 18, spinal cords from the animals were analyzed by Luxol Fast Blue staining.
- FIG. 10 Suppression of experimental autoimmune encephalomyelitis mediated by MOG35 -55 -pulsed 1 ⁇ -hydroxylase-overexpressing BM-DCs requires foxp3 + Treg cells.
- C57BL/6 mice were immunized with MOG35-55 for the induction of EAE. The animals received either no treatment (filled triangles) or 1 x 10 6 MOG 35 -55-pulsed immunogenic but non-proliferative mDC-CYP cells (open circles and open triangles).
- an anti-CD25 monoclonal antibody clone PC61, 500 ⁇ g/mouse/injection
- FIG. 11A-11C Delivery of the active vitamin D metabolite to immune synapses reduces expression of CXCR3 on CD4 + T cells.
- CFA Complete Freund Adjuvant
- CFA Complete Freund Adjuvant
- splenocytes from the animals were analyzed for the expression of CXCR3 on CD4 + T cells by flow cytometry.
- A Gating strategy.
- B Representative plots showing CXCR3 expression on CD4 + T cells.
- FIG. 12 A model of myelin-specific immune suppression mediated by lct- hydroxylase-overexpressing dendritic cells.
- a myelin-antigen-pulsed DC-CYP upon in vivo administration, specifically migrates into the peripheral lymphoid tissues where it interacts with myelin-specific T cells and at the same time actively de novo synthesizes a high l,25(OH) 2 D concentration at the interface of the DC-CYP and the myelin-specific T cells.
- the DC-CYP is self-tolerized and becomes TolDC-CYP through l,25(OH) 2 D's intracrine and/or paracrine action. Additionally, the myelin-specific T cells differentiate into Treg cells through the paracrine action of l,25(OH) 2 D. Consequently, the newly induced myelin-specific Treg cells provide myelin-specific suppression of EAE.
- compositions and methods for treating immune-mediated diseases such as but not limited to multiple sclerosis and rheumatoid arthritis
- immune-mediated diseases such as but not limited to multiple sclerosis and rheumatoid arthritis
- engineered dendritic cells that overexpress 1 ⁇ -hydroxylase and method of treating multiple sclerosis comprising administering the engineered dendritic cells to a subject in need thereof, are provided.
- Multiple sclerosis (MS) is a disease characterized by chronic inflammation, demyelination, and axonal loss in the central nervous system, in which myelin sheaths around the axons of the brain and spinal cord are damaged.
- autoimmune inflammatory attack of the myelin sheath causes demyelination.
- the ultimate goal of MS therapy is to stop progression of the disease without interfering with global immune defense mechanisms.
- currently available medications have not met this goal because the current therapies block in the immune system one or more components that mediate the inflammatory disorder in the CNS of MS patients.
- these blocked immune components also participate in the general immune defense against infections and cancers. Consequently, normal immune defense mechanisms are attenuated, which leads to predictable adverse effects. For this reason, active investigations into more specific blocking of the immune attack of one's own myelin sheath are being pursued to increase efficacy of the therapy and to mitigate side effects.
- AST antigen-specific therapy
- AST is a major sought goal in the treatment of MS.
- AST has a unique advantage in that it aims to specifically block immune attack of myelin sheath and hence prevent undesirable side effects which are frequently associated with the currently available therapies and caused by unintended suppression of immunity.
- DCs programmed dendritic cells
- Treg myelin-specific regulatory T
- the cells, compositions, and methods disclosed herein resolve the instability issue associated with the use of DCs for augmentation of myelin-specific Treg cells in vivo.
- a therapeutic strategy is provided that does not depend on functional status of DCs, meaning that the use of both non-immunogenic and immunogenic DCs can have therapeutic effects. If the use of immunogenic DCs is effective, then the use of non-immunogenic DCs can be expected to be effective as well. Accordingly, some embodiments herein disclosed focused on evaluating whether engineered immunogenic DCs would be able to suppress ongoing EAE. As described below in the Examples section and in FIGS. 3A-3B, although parental immunogenic DCs worsened EAE, ⁇ -hydroxylase-overexpressing immunogenic DCs effectively suppressed the progression of EAE.
- the present disclosure relates to a novel therapy that helps resolve the DC conversion concern.
- engineered DCs are disclosed that can de novo synthesize the active vitamin D metabolite (i.e., l,25[OH] 2 D, also referred to as calcitriol).
- DCs are engineered for de novo production of the Treg-inducing calcitriol concentration by overexpressing 1 ⁇ -hydroxylase in the DCs.
- the engineered DCs synthesize a supra-physiological calcitriol concentration.
- immunization with such engineered DCs can induce Treg cells and suppress disease progression.
- de novo synthesized calcitriol can entail several outcomes.
- calcitriol has been shown under certain conditions to tolerize both animal and human DCs in ex vivo cultures.
- intracrine, autocrine, and/or paracrine effects of calcitriol produced by the engineered DCs can be sufficient to suppress potential immunogenicity of in vivo converted engineered DCs, thereby circumventing the concern of conversion of the engineered DCs into pathogenic DCs.
- calcitriol produced by the engineered DCs can program Treg cells at DC-T cell interfaces (immune synapses) during DC-T cell interaction in the peripheral lymphoid tissues, hence augmenting immune regulation and treating MS.
- the de novo synthesis of calcitriol can ensure generation of a focal Treg- inducing calcitriol concentration in peripheral lymphoid tissues.
- nonproliferative DCs can achieve the in vivo presence of the engineered DCs within a short period of time that is sufficient for Treg induction.
- Both de novo calcitriol synthesis and non-proliferative status of the DCs can prevent a potential massive increase of circulating calcitriol level in systemic circulation. As a result, it can reduce side effects (e.g., hypercalcemia) in response to a high circulating level of calcitriol.
- engineered cells are used to induce Treg cells in vivo with a safe profile.
- DCs are engineered to overexpress 1 ⁇ -hydroxylase such that the engineered DCs can de novo synthesize a supra- physiological calcitriol concentration at DC-T cell interfaces (immune synapses) during DC-T cell interaction in the peripheral lymphoid tissues.
- the expression of 1 ⁇ -hydroxylase in parental BM-DCs and engineered DCs confirmed functional overexpression of 1 ⁇ -hydroxylase by transducing the parental DCs with a lentiviral vector that expressed CYP27B1 gene (the gene that encodes 1 ⁇ - hydroxylase).
- 1 ⁇ -hydroxylase refers to 25-hydroxyvitamin D-l alpha hydroxylase
- 1 ⁇ -hydroxylase is an enzyme that catalyzes the conversion of 25- hydroxyvitamin D3 (25(OH)D) to 1,25-dihydroxyvitamin D3 (l,25(OH) 2 D).
- the gene that encodes 1 ⁇ -hydroxylase is a human cytochrome P450 family 27 subfamily B member 1 (CYP27B1). Sequences for human CYP27B1 mRNA and 1 ⁇ -hydroxylase protein are set forth in, e.g., NCBI GenBank Accession Nos. NM_000785.3 and NP_000776.1, respectively.
- a dendritic cell as described herein is engineered to express a 1 ⁇ - hydroxylase protein that has at least 70%, at least 75% at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the 1 ⁇ -hydroxylase protein set forth in NCBI GenBank Accession No. NP_000776.1.
- identity in the context of two or more polynucleotide or polypeptide sequences, refer to two or more sequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (e.g., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity) over a specified region.
- Methods for comparing polynucleotide or polypeptide sequences and determining percent identity are described in the art. See, e.g., Roberts et al., BMC Bioinformatics, 7:382, 2006, incorporated by reference herein.
- nucleic acid and “polynucleotide” are used interchangeably herein and refer to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, and complements thereof.
- the polynucleotide is DNA (e.g., genomic DNA or cDNA).
- the polynucleotide is RNA (e.g., mRNA).
- nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), polymorphic variants (e.g., SNPs), splice variants, and nucleic acid sequences encoding truncated forms of proteins, complementary sequences, as well as the sequence explicitly indicated.
- protein and “polypeptide” are used interchangeably herein and refer to a polymer of amino acid residues. As used herein, the terms encompass amino acid chains of any length, including full-length proteins and truncated proteins.
- a promoter refers to a polynucleotide sequence capable of driving transcription of a coding sequence in a cell.
- a promoter includes cis-acting transcriptional control elements and regulatory sequences that are involved in regulating or modulating the timing and/or rate of transcription of a gene.
- a promoter can be a cis-acting transcriptional control element, including an enhancer, a promoter, a transcription terminator, an origin of replication, a chromosomal integration sequence, 5' and 3' untranslated regions, or an intronic sequence, which are involved in transcriptional regulation.
- tissue-specific promoter initiates transcription only in one or a few particular tissue types.
- a polynucleotide sequence is "heterologous" to an organism or a second polynucleotide sequence if it originates from a foreign species, or, if from the same species, is modified from its original form.
- a promoter when a promoter is said to be operably linked to a heterologous coding sequence, it means that the coding sequence is derived from one species whereas the promoter sequence is derived another, different species; or, if both are derived from the same species, the coding sequence is not naturally associated with the promoter (e.g., the promoter is from a different gene in the same species).
- immune-mediated disease refers to a disease that results from a dysregulation of normal immune response in a subject.
- the immune-mediated disease is an autoimmune disease (e.g., multiple sclerosis, lupus, or rheumatoid arthritis).
- the immune-mediated disease is a demyelinating disease.
- demyelinating disease refers to a disease or condition of the nervous system characterized by damage to or loss of the myelin sheath of neurons.
- a demyelinating disease can be a disease affecting the central nervous system or a disease affecting the peripheral nervous system.
- demyelinating diseases include, but are not limited to, multiple sclerosis, idiopathic inflammatory demyelinating disease, transverse myelitis, Devic's disease, progressive multifocal leukoencephalopathy, optic neuritis, leukoystrophy, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, autoimmune peripheral neuropathy, Charcot-Marie-Tooth disease, acute disseminated encephalomyelitis, adrenoleukodystrophy, adrenomyeloneuropathy, Leber's hereditary optic neuropathy, or HTLV-associated myelopathy.
- the demyelinating disease is multiple sclerosis.
- a "subject" is a mammal, in some embodiments, a human. Mammals can also include, but are not limited to, farm animals (e.g., cows, pigs, horses, chickens, etc.), sport animals, pets, primates, horses, dogs, cats, mice and rats.
- farm animals e.g., cows, pigs, horses, chickens, etc.
- sport animals e.g., pets, primates, horses, dogs, cats, mice and rats.
- treatment refers to any indicia of success in the treatment or amelioration of an injury, disease, or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, disease, or condition more tolerable to the subject; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; and/or improving a subject's physical or mental well-being.
- a "therapeutic amount” or a "therapeutically effective amount” of an agent is an amount of the agent that prevents, alleviates, abates, or reduces the severity of symptoms of a disease (e.g., an immune-mediated disease, e.g., MS) in a subject.
- a therapeutically effective amount will show an increase or decrease of therapeutic effect of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%.
- Therapeutic efficacy can also be expressed as "fold" increase or decrease.
- a therapeutically effective amount can have at least a 1.2-fold, 1.5- fold, 2-fold, 5-fold, or more effect over a control.
- administer refers to introducing an agent (e.g., an engineered dendritic cell, population of engineered dendritic cells, or pharmaceutical composition comprising an engineered dendritic cell as described herein) into a subject or patient, such as a human.
- agent e.g., an engineered dendritic cell, population of engineered dendritic cells, or pharmaceutical composition comprising an engineered dendritic cell as described herein
- the terms encompass both direct administration, (e.g., self-administration or administration to a patient by a medical professional) and indirect administration (e.g., the act of prescribing a compound or composition to a subject).
- pharmaceutical composition refers to a composition suitable for administration to a subject.
- a pharmaceutical composition is sterile, and preferably free of contaminants that are capable of eliciting an undesirable response with the subject.
- Pharmaceutical compositions can be designed for administration to subjects in need thereof via a number of different routes of administration, including oral, intravenous, buccal, rectal, parenteral, intraperitoneal, intradermal, intratracheal, intramuscular, subcutaneous, inhalational, and the like.
- dendritic cells that have been engineered to express or overexpress a 1 ⁇ -hydroxylase are provided.
- the dendritic cell comprises a heterologous polynucleotide that encodes a 1 ⁇ -hydroxylase protein.
- the dendritic cell can be obtained or derived from any suitable source.
- the dendritic cell is a bone marrow-derived dendritic cell.
- the dendritic cell is a cord blood-derived dendritic cell.
- the dendritic cell is a peripheral blood-derived dendritic cell.
- the dendritic cell comprises a polynucleotide comprising a human cytochrome P450 family 27 subfamily B member 1 (CYP27B1) polynucleotide sequence (e.g., the polynucleotide sequence of NCBI GenBank Accession No. NM_000785.3 or a variant thereof).
- the polynucleotide encodes a human 1 ⁇ - hydroxylase protein having the sequence of the 1 ⁇ -hydroxylase protein set forth in NCBI GenBank Accession No.
- NP_000776.1 or a variant thereof (e.g., a protein that has at least 70%, at least 75% at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the 1 ⁇ -hydroxylase protein set forth in NCBI GenBank Accession No. NP_000776.1).
- the engineered dendritic cell overexpresses the lct- hydroxylase protein, as compared to a dendritic cell lacking the heterologous polynucleotide.
- the dendritic cell comprising a heterologous polynucleotide expresses the 1 ⁇ -hydroxylase protein at a level that is at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 30-fold, at least 40-fold, or at least 50-fold higher than a dendritic cell lacking the heterologous polynucleotide.
- Protein expression can be detected and quantified using routine techniques such as immunoassays, two-dimensional gel electrophoresis, and quantitative mass spectrometry that are known to those skilled in the art. Protein quantification techniques are generally described in "Strategies for Protein Quantitation,” Principles of Proteomics, 2nd Edition, R. Twyman, ed., Garland Science, 2013.
- protein expression is detected by immunoassay, such as but not limited to enzyme immunoassays (EIA) such as enzyme multiplied immunoassay technique (EMIT), enzyme-linked immunosorbent assay (ELISA), IgM antibody capture ELISA (MAC ELISA), and microparticle enzyme immunoassay (MEIA); capillary electrophoresis immunoassays (CEIA); radioimmunoassays (RIA); immunoradiometric assays (IRMA); immunofluorescence (IF); fluorescence polarization immunoassays (FPIA); and chemiluminescence assays (CL).
- EIA enzyme multiplied immunoassay technique
- ELISA enzyme-linked immunosorbent assay
- MAC ELISA IgM antibody capture ELISA
- MEIA microparticle enzyme immunoassay
- CEIA capillary electrophoresis immunoassays
- RIA radioimmunoassays
- IRMA immunoradiometric
- protein expression is detected by quantitative mass spectrometry, for example but not limited to, spectral count MS, ion intensities MS, metabolic labeling (e.g., stable-isotope labeling with amino acids in cell culture (SILAC), enzymatic labeling, isotopic labeling (e.g., isotope-coded protein labeling (ICPL) or isotope-coded affinity tags (ICAT)), and isobaric labeling (e.g., tandem mass tag (TMT)).
- quantitative mass spectrometry for example but not limited to, spectral count MS, ion intensities MS, metabolic labeling (e.g., stable-isotope labeling with amino acids in cell culture (SILAC), enzymatic labeling, isotopic labeling (e.g., isotope-coded protein labeling (ICPL) or isotope-coded affinity tags (ICAT)), and isobaric labeling (e.g., tandem mass tag (TMT)).
- the heterologous polynucleotide that encodes a 1 ⁇ - hydroxylase protein is operably linked to a promoter.
- the dendritic cell comprises a polynucleotide encoding a 1 ⁇ -hydroxylase protein (e.g., a polynucleotide comprising a human cytochrome P450 family 27 subfamily B member 1 (CYP27B1) polynucleotide sequence such as the polynucleotide sequence of NCBI GenBank Accession No. NM_0007S5.3) that is operably linked to a promoter.
- the promoter is a constitutively active promoter.
- Suitable promoters include, but are not limited to, a spleen focus-forming virus (SFFV) promoter, a phosphoglycerate kinase (PGK) promoter, EFla promoter, a cytomegalovirus (CMV) promoter, a Rous sarcoma virus promoter, a simian virus 40 (SV40) early promoter, a mouse mammary tumor virus promoter, a Moloney virus promoter, an avian leukemia virus promoter, or an Epstein-Barr virus immediate early promoter.
- the promoter is an inducible promoter (e.g., a tetracycline-inducible promoter).
- the promoter is a tissue-specific promoter (e.g., a dendritic cell-specific promoter, e.g., a CDllc promoter or a DC-STAMP promoter).
- the promoter is a SFFV promoter or a PGK promoter.
- the engineered dendritic cell comprises an expression cassette that comprises a promoter operably linked to a heterologous polynucleotide that encodes a 1 ⁇ -hydroxylase protein (e.g., a promoter operably linked to a polynucleotide comprising a human cytochrome P450 family 27 subfamily B member 1 (CYP27B1) polynucleotide sequence such as the polynucleotide sequence of NCBI GenBank Accession No. NM_000785.3).
- the engineered dendritic cell comprises a vector that comprises an expression cassette that comprises a promoter operably linked to a heterologous polynucleotide that encodes a 1 ⁇ -hydroxylase protein.
- the polynucleotide that encodes a 1 ⁇ -hydroxylase protein is expressed in the dendritic cell using a virus or viral vector.
- the virus is an adenovirus, lentivirus, adeno-associated virus, or retrovirus.
- the virus is a lentivirus.
- Viruses and viral vectors containing the polynucleotide that encodes a 1 ⁇ -hydroxylase protein can be introduced into the dendritic cell by methods known in the art, such as but not limited to, transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, or lipofection.
- the engineered dendritic cell is activated.
- the dendritic cell is activated by stimulating the cell with an antigen, such as lipopolysaccharide (LPS).
- the dendritic cell is activated by stimulating the cell with a cytokine, such as TNF- ⁇ .
- the engineered dendritic cell is pulsed with an antigen peptide.
- the antigen peptide is a peptide of a myelination protein.
- the antigen peptide is a peptide of myelin basic protein (MBP), proteolipid protein (PLP), or myelin oligodendrocyte glycoprotein (MOG), or a combination thereof.
- the peptide comprises at least 9, 12, 15, 18, 21, 14, 17, 30, 40, 50, 60, 70, 80, 90, 100 contiguous amino acids of a MBP, PLP, or MOG protein.
- the peptide is a MOG peptide, such as MOG peptide 35-55 (MOG 35-55 ), MOG peptide 89-113 (MOG 89- ii 3 ), or MOG peptide 92-106 (MOG 92- io6).
- MOG peptide 35-55 MOG 35-55
- MOG peptide 89-113 MOG 89- ii 3
- MOG peptide 92-106 MOG 92- io6
- the peptide is a MBP peptide, such as MBP peptide 4-14 (MBP 4- i 4 ), MBP peptide 68-86 (MBP 68-8 6), MBP peptide 84-97 (MBP 84-97 ), MBP peptide 84-105 (MBP 84-105 ), MBP peptide 87-99 ( ⁇ 87-99 ), or MBP peptide 90-106 (MBPgo-ioe)- Methods for peptide pulsing are known in the art. See, e.g., O'Neill et al., Methods Mol Med, 2005, 109:97-112.
- the engineered dendritic cell is treated with an antiproliferative agent.
- the anti-proliferative agent is irradiation (e.g., gamma irradiation).
- the anti-proliferative agent is a chemical compound (e.g., mitomycin C).
- the engineered dendritic cell is capable of de novo synthesizing 1,25-dihydroxyvitamin D when cultured in the presence of 25-hydroxyvitamin D. In some embodiments, the engineered dendritic cell synthesizes 1,25-dihydroxyvitamin D at an increased level, relative to a control dendritic cell lacking the heterologous polynucleotide that encodes the lct-hydroxylase protein, when cultured in the presence of 25-hydroxyvitamin D.
- the engineered dendritic cell synthesizes at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% more 1,25-dihydroxyvitamin D, when cultured in the presence of 25-hydroxyvitamin D, as compared to a control dendritic cell.
- the engineered dendritic cell synthesizes 1,25-dihydroxyvitamin D at a level that is increased by at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 15-fold, at least 20-fold or more, when cultured in the presence of 25-hydroxyvitamin D, as compared to a control dendritic cell.
- Measurement of the 1 ⁇ -hydroxylase enzymatic activity of the engineered dendritic cell can be performed according to methods known in the art. In some embodiments, measurement of 1 ⁇ -hydroxylase enzymatic activity is performed as described in the Examples section below or in Li ef al, FASEB J., 2017, doi:10.1096/fj.201601243R, incorporated by reference herein.
- compositions and Kits [0068]
- compositions comprising an engineered dendritic cell or population of engineered dendritic cells as described herein are provided.
- the composition further comprises a pharmaceutically acceptable excipient.
- Guidance for preparing formulations for use in the present invention is found in, for example, Remington: The Science and Practice of Pharmacy, 21st Edition, Philadelphia, PA. Lippincott Williams & Wilkins, 2005.
- a pharmaceutical composition comprises an acceptable carrier and/or excipients.
- a pharmaceutically acceptable carrier includes any solvents, dispersion media, or coatings that are physiologically compatible and that preferably does not interfere with or otherwise inhibit the activity of the therapeutic agent.
- the carrier is suitable for intravenous, intramuscular, oral, intraperitoneal, transdermal, topical, or subcutaneous administration.
- Pharmaceutically acceptable carriers can contain one or more physiologically acceptable compound(s) that act, for example, to stabilize the composition or to increase or decrease the absorption of the active agent(s).
- Physiologically acceptable compounds can include, for example, carbohydrates, such as glucose, sucrose, or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins, compositions that reduce the clearance or hydrolysis of the active agents, or excipients or other stabilizers and/or buffers.
- carbohydrates such as glucose, sucrose, or dextrans
- antioxidants such as ascorbic acid or glutathione
- chelating agents such as ascorbic acid or glutathione
- low molecular weight proteins compositions that reduce the clearance or hydrolysis of the active agents, or excipients or other stabilizers and/or buffers.
- Other pharmaceutically acceptable carriers and their formulations are well-known and generally described in, for example, Remington: The Science and Practice of Pharmacy, supra.
- Various pharmaceutically acceptable excipients are well-known in the art and can be found in, for example, Handbook of Pharmaceutical Excipients (5 ed., Ed. Rowe et al., Pharmaceutical Press
- the engineered dendritic cell or population of engineered dendritic cells can be formulated into preparations by dissolving, suspending or emulsifying them in an aqueous or nonaqueous solvent, such as vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, stabilizers and preservatives.
- an aqueous solution is used, such as a physiologically compatible buffer such as Hanks's solution, Ringer's solution, or physiological saline buffer.
- Formulations for injection can be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative.
- kits comprising the engineered dendritic cells, populations of engineered dendritic cells, or pharmaceutical compositions comprising an engineered dendritic cell as described herein are provided.
- the kit further comprises one or more additional agents, e.g., vitamin D, vitamin D3, or 25-hydroxyvitamin D3 (25(OH)D).
- a kit further comprises instructional materials containing directions (i.e., protocols) for the practice of the methods of this invention (e.g., instructions for using the kit for treating an immune-mediated disease). While the instructional materials typically comprise written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this disclosure. Such media include, but are not limited to electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. Such media may include addresses to internet sites that provide such instructional materials.
- the method comprises administering to the subject an engineered dendritic cell that expresses a heterologous polynucleotide that encodes a 1 ⁇ -hydroxylase (e.g., a heterologous polynucleotide comprising a human cytochrome P450 family 27 subfamily B member 1 (CYP27B1) polynucleotide sequence, operably linked a heterologous promoter), or a composition comprising a population of the engineered dendritic cells or a pharmaceutical composition comprising the engineered dendritic cell.
- a heterologous polynucleotide that encodes a 1 ⁇ -hydroxylase e.g., a heterologous polynucleotide comprising a human cytochrome P450 family 27 subfamily B member 1 (CYP27B1) polynucleotide sequence, operably linked a heterologous promoter
- CYP27B1 human cytochrome P450 family 27 subfamily B member 1
- the therapeutic methods comprise administering to the subject an engineered dendritic cell, population of engineered dendritic cells, or pharmaceutical composition comprising an engineered dendritic cell as described herein (e.g., as described in Section III above).
- the engineered dendritic cell is an activated dendritic cell.
- the engineered dendritic cell has reduced proliferative ability (e.g., due to treatment with an anti-proliferative agent).
- the engineered dendritic cell has been pulsed with an antigen peptide (e.g., a peptide of a myelination protein, such as MOG, MBP, PLP, or a combination thereof).
- the cells and methods herein disclosed can be used to treat immune-mediated diseases in humans.
- DCs can be generated from peripheral blood mononuclear cells in the presence of IL-4 and GM-CSF, which are the same cytokines used in the mouse model.
- the DCs can be engineered to overexpress the lct- hydroxylase by an FDA-approved viral vector (e.g. an adeno-associated viral vector).
- the engineered cells can then be pulsed with one or more human myelin epitopes (equivalent to MOG 35-55 in the mouse model).
- Such epitope-pulsed engineered DCs can be treated to prevent further proliferation by mitomycin C or by irradiation (2500 Rads).
- These non- proliferative, epitope-pulsed, engineered DCs can be intravenously or subcutaneously injected into a patient who has the immune-mediated disease.
- the subject to be treated is a human. In some embodiments, the subject is an adult. In some embodiments, the subject is a juvenile.
- the subject to be treated has an autoimmune disease.
- the subject to be treated has a demyelinating disease.
- the demyelinating disease is multiple sclerosis, idiopathic inflammatory demyelinating disease, transverse myelitis, Devic's disease, progressive multifocal leukoencephalopathy, optic neuritis, leukodystrophy, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, autoimmune peripheral neuropathy, Charcot- Marie-Tooth disease, acute disseminated encephalomyelitis, adrenoleukodystrophy, adrenomyeloneuropathy, Leber's hereditary optic neuropathy, or human T-cell lymphotropic virus (HTLV)-associated myelopathy.
- HTLV human T-cell lymphotropic virus
- the subject has multiple sclerosis (MS). There are several subtypes of MS, including relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), primary progressive multiple sclerosis (PPMS), and progressive relapsing multiple sclerosis (PRMS).
- RRMS relapsing-remitting multiple sclerosis
- SPMS secondary progressive multiple sclerosis
- PPMS primary progressive multiple sclerosis
- PRMS progressive relapsing multiple sclerosis
- the subject has RRMS.
- SPMS secondary progressive multiple sclerosis
- PPMS primary progressive multiple sclerosis
- PRMS progressive relapsing multiple sclerosis
- the subject has RRMS.
- SPMS secondary progressive multiple sclerosis
- PPMS primary progressive multiple sclerosis
- PRMS progressive relapsing multiple sclerosis
- PRMS progressive relapsing multiple sclerosis
- the subject has RRMS.
- SPMS secondary progressive multiple sclerosis
- PPMS primary progressive multiple
- the route of administration of an engineered dendritic cell, population of engineered dendritic cells, or pharmaceutical composition comprising an engineered dendritic cell as described herein can be oral, intraperitoneal, transdermal, subcutaneous, intravenous, intramuscular, inhalational, topical, intralesional, rectal, intrabronchial, intralymphatic, intradermal, nasal, transmucosal, intestinal, ocular or otic delivery, or any other methods known in the art.
- an engineered dendritic cell, population of engineered dendritic cells, or pharmaceutical composition comprising an engineered dendritic cell as described herein is administered by intravenous injection or by subcutaneous injection. In some embodiments, an engineered dendritic cell, population of engineered dendritic cells, or pharmaceutical composition comprising an engineered dendritic cell as described herein is administered systemically. In some embodiments, an engineered dendritic cell, population of engineered dendritic cells, or pharmaceutical composition comprising an engineered dendritic cell as described herein is administered locally.
- a therapeutically effective amount of engineered dendritic cells or composition comprising engineered dendritic cells is an amount that prevents or reverses one or more symptoms of an immune-mediated disease (e.g., MS).
- an immune-mediated disease e.g., MS
- a therapeutically effective amount is at least about 100, 500, 1,000, 2,500, 5,000, 10,000, 20,000, 50,000, 100,000, 500,000, 1,000,000, 5,000,000, or 10,000,000 cells or more (e.g., per administration).
- a therapeutically effective amount of the engineered dendritic cells or composition comprising engineered dendritic cells is administered about once per day, once per week, twice per week, once per month, or twice per month.
- the engineered dendritic cells, populations of engineered dendritic cells, and compositions comprising engineered dendritic cells may be administered to a subject in need thereof for a predetermined time, an indefinite time, or until an endpoint is reached.
- treatment is continued on a continuous daily or weekly basis for at least two to three months, six months, one year, or longer.
- treatment is for at least 30 days, at least 60 days, at least 90 days, at least 120 days, at least 150 days, or at least 180 days.
- treatment is continued for at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, or at least one year.
- treatment is continued for the rest of the patient's life or until administration is no longer effective to provide meaningful therapeutic benefit.
- the engineered dendritic cells, populations of engineered dendritic cells, or compositions comprising engineered dendritic cells are administered in combination with one or more additional agents.
- the engineered dendritic cells, populations of engineered dendritic cells, or compositions comprising engineered dendritic cells are administered in combination with vitamin D, vitamin D3, or 25-hydroxyvitamin D3 (25(OH]D).
- the administration may be concurrent or sequential.
- methods of inducing regulatory T cells are provided.
- the method comprises contacting one or more T cells with an engineered dendritic cell, population of engineered dendritic cells, or composition comprising an engineered dendritic cell as described herein (e.g., in Section III above).
- the T cells are myelin-specific T cells.
- the regulatory T cells that are induced are Foxp3 + Treg cells. In some embodiments, the regulatory T cells that are induced are T h 2 cells. In some embodiments, the regulatory T cells that are induced are Trl cells.
- the method of contacting one or more T cells with an engineered dendritic cell, population of engineered dendritic cells, or composition comprising an engineered dendritic cell as described herein is carried out in vivo (e.g., in a human subject).
- the method of contacting one or more T cells with an engineered dendritic cell, population of engineered dendritic cells, or composition comprising an engineered dendritic cell is carried out in vitro.
- the regulatory T cells that are induced in vitro are optionally expanded and subsequently administered to a subject.
- the T cells are autologous to the subject to be treated.
- the T cells are allogeneic to the subject to be treated.
- Disclosed herein is a novel engineered dendritic cell that augments myelin-specific immune regulation and works with immunogenic DCs.
- This engineered DC carries an overexpressed enzyme, 25-hydroxyvitamin D lct-hydroxylase ("1 ⁇ -hydroxylase") that, under physiologic conditions, synthesizes the active vitamin D metabolite 1,25-dihydroxyvitamin D ("l,25(OH) 2 D").
- mice Female C57BL/6 mice aged 4 to 6 weeks were obtained from The Jackson Laboratory. All animals were housed in specific pathogen-free environment and were cared for in accordance with institutional and National Institutes of Health (NIH) guidelines. Animals were acclimated to new housing conditions for a minimum of 5 days before experimentation. Experiments were conducted with approval of the Institutional Animal Care and Use Committee at Loma Linda University, Loma Linda, California, USA.
- NASH National Institutes of Health
- DC2.4 is a DC line generated from bone marrow-derived DCs. Lentivirus production
- the 293T cells (5 x 10 6 cells in 1 mL) were seeded into a 15 cm culture dish, which was pre-coated with the L-lysine, in standard DMEM culture medium containing 10% fetal bovine serum (FBS) and antibiotics one day before the transfection.
- FBS fetal bovine serum
- the cells were incubated at 37°C, 5% C0 2 overnight and then replenished with DMEM culture medium containing 4% FBS, antibiotics, and 20 mM Hepes. Supernatant was collected on the 2 nd and 3 rd days. The collected supernatants were centrifuged (4800 g) at 4°C for 24 hours. The viruses were re-suspended in PBS containing 5% glycerol, stored in -80°C, and used for transducing the 293T cells or the DCs. Generation of bone marrow-derived DCs and transduction of the DCs with the lentivirus
- Bone marrow mononuclear cells were isolated from mouse (6-8 weeks old) tibias and femurs and cultured at a density of 1 x 10 6 cells/mL in 6-well plates in RPMI1640 medium supplemented with 10% FBS, 100 U/mL recombinant murine granulocyte/macrophage colony- stimulating factor (GM-CSF), and 10 U/ml murine interleukin-4 (IL-4) (Peprotech, Rocky Hill, NJ, USA).
- Non-adherent cells were gently washed out after 48 hr of culture; the remaining loosely adherent clusters were cultured for another 48 hr and harvested for lentivirus transduction.
- mice were immunized subcutaneously with 200 ug of the MOG 35-55 emulsified in Incomplete Freund Adjuvant (IFA) supplemented with 250 ⁇ g of heat-inactivated Mycobacterium tuberculosis H37Ra (Difco Laboratories, Michigan, USA).
- IFA Incomplete Freund Adjuvant
- Mycobacterium tuberculosis H37Ra Heat-inactivated Mycobacterium tuberculosis H37Ra
- each mouse was administered 150 ng of pertussis toxin (Calbiochem, Germany) intraperitoneally. Animals were clinically scored and weighed on a daily basis for up to 40 days after disease induction.
- T cells isolated from splee ns were co-cultured with MOG 35-55 pulsed DCs at a T:DC ratio of 4:1 in RPMI 1640 medium containing 100 ⁇ MOG 35-55 , 10% FBS, and antibiotics. Two days later, supernatants were collected for cytokine measurements.
- a BD Cytometric Beads Array® (BD Biosciences, San Jose, CA, USA) kit was used for cytokine measurements according to the manufacturer's instruction.
- the test cytokines included interleukin-2 (IL- 2), interleukin-4 (IL-4), interleukin-6 (IL-6), and interleukin-10 (IL-10).
- FIG. 1A depicts a schematic representation of the lenti-CYP-GFP vector that was used to transduce parental bone- marrow-derived dendritic cells (BM-DCs), which express a low level of 1 ⁇ -hydroxylase, with CYP27B1 (cytochrome P450 family 27 subfamily B member 1) gene to overexpress 1 ⁇ - hydroxylase for de novo synthesis of a supra-physiological calcitriol concentration.
- BM-DCs parental bone- marrow-derived dendritic cells
- CYP27B1 cytochrome P450 family 27 subfamily B member 1
- IB is a panel of photomicrographs that show production of green fluorescence protein (GFP) in transfected BM-DCs after 24 and 48 hours post-transfection.
- the transduced DCs overexpressed GFP and presumably 1 ⁇ -hydroxylase as well.
- FIG. 1C real time PCR confirmed specific overexpression of the CYP27B1 mRNA in the DCs transduced with the lenti-CYP-GFP.
- the functional activity of the overexpressed 1 ⁇ -hydroxylase was assessed by adding 25[OH]D into the DC cultures. After overnight incubation, supernatants were collected and analyzed for the production of l,25[OH] 2 D by a radioimmunoassay (RIA).
- RIA radioimmunoassay
- ID illustrates that DCs transduced with the lenti-CYP-GFP, as compared to control DC cells, de novo synthesized a significantly higher level of l,25[OH] 2 D in the presence of the 1 ⁇ - hydroxylase substrate.
- Parental BM-DCs can synthesize calcitriol from 25[OH]D (the 1 ⁇ - hydroxylase substrate), suggesting that a low level of 1 ⁇ -hydroxylase activity was present.
- FIGS. 2A-2C illustrate that the 1 ⁇ -hydroxylase-overexpressing BM-DCs maintain important DC functions, e.g. lymphoid tissue-homing capacity, such that the engineered DCs could induce Treg cells in the peripheral lymphoid tissues upon in vivo delivery.
- FIG. 2A flow cytometry analysis indicates 1 ⁇ -hydroxylase overexpression does not alter the expression of activation markers on the cell surface of the engineered DCs.
- the expressions of the markers MHC II, CD80, and CD86 were not significantly changed in 1 ⁇ -hydroxylase- overexpressing BM-DCs compared to controls.
- FIG. 2B illustrates that the engineered DCs maintain lymphoid tissue-homing capacity.
- FIG. 2C shows that the engineered DCs successfully migrated into the spleen three days after the DC injection.
- FIGS. 3A-3B illustrate that the lymphoid-homing, engineered DC2.4 cells can a therapeutic agent for inducing myelin-specific immune regulation in mice that were immunized with MOG 35-55 for EAE, an animal model for human MS.
- the effects of immunogenic (activated or mature) and non-proliferative (i.e., mytomycin C treated) parental DC2.4 cells (mDC2.4) on EAE disease course were examined.
- the effects of immunogenic DCs were evaluated to determine whether the engineered DCs, when activated in a pro-inflammatory in vivo environment, would still have a therapeutic effect.
- non-proliferative DCs were used to prevent undesirable side effects that may be caused by unnecessary presence of the engineered DC in vivo for a long period of time.
- animals intravenously injected with the parental mDCs displayed significantly enhanced disease activity, indicating that non- modified DCs were pathogenic.
- EAE disease course was also evaluated in animals intravenously injected with non-proliferative DC2.4 cells transduced with the lenti-CYP-GFP.
- the engineered immunogenic and non-proliferative DC2.4 cells which were pulsed with MOG 35-55 (mDC2.4-CYP-MOG35.55), were intravenously injected into animals at the time when the paralytic symptoms just began (i.e., at day 10).
- This pulsing of MOG 35-55 ensured that the engineered DCs would mainly interact with MOG35 -55 -specific T cells (i.e., the pathogenic T cells).
- FIG. 3B and in Table 1 below a single injection of such engineered DCs markedly suppressed the paralytic disease. This therapeutic effect was reproduced in two subsequent independent experiments.
- FIG. 4A depicts a schematic of the experimental protocol. Animals were immunized with MOG 35-55 emulsified in Complete Freund Adjuvant (CFA). Four days later, either parental DCs or the engineered DCs (DC-CYP) were subcutaneously injected into the EAE-bearing mice. At day 10, T cell apoptosis was examined by Annexin and PI staining using fluorescence-activated cell sorting (FACS) flow cytometry.
- FACS fluorescence-activated cell sorting
- FIG. 4B illustrates the gating strategy used for flow cytometry analysis.
- FIG. 4C shows representative FACS plots showing Annexin and PI staining in all CD4 + and CD8 + T cells.
- the DC-CYP cells significantly increased apoptosis of CD4 + (by ⁇ 30%), but not of CD8 + , T cells in local draining lymph nodes.
- calcitriol can induce regulatory T cells. Accordingly, T cell populations were analyzed to determine whether subsets of regulatory T cells were induced by the lot-hydroxylase-overexpressing BM-DCs.
- FIG. 5A depicts a schematic of the experimental protocol.
- FIG. 5B illustrates the gating strategy used for flow cytometry analysis.
- the engineered DCs compared to no treatment controls, significantly increased expression of IL-10 by almost 10-fold in T cells, suggesting that the engineered DCs induced IL-10 + Treg cells.
- FIG. 5C illustrates the gating strategy used for flow cytometry analysis.
- FIG. 5D shows that secretion of Th2 cytokines IL-4, IL-5, IL-6, and IL-13 were also significantly increased by 2- to 4-fold, indicating that the engineered DCs created in the peripheral lymphoid tissues a microenvironment that favors Th2 differentiation.
- FIG. 6 illustrates that the profile of cytokine secretion by these cells (as assessed in the cell culture supernatants with a Cytometric Beads Array assay for T cell cytokine secretion) was similar to what was observed by intracellular cytokine staining.
- FIG. 7A-7E shows that engineered DCs stimulate the expression of Th2 and Trl cytokines in CD4 + T cells. Animals were immunized as shown in FIG. 7A.
- C57BL/6 mice were immunized with MOG 35-55 emulsified in CFA for the induction of EAE, as shown in FIG. 9A.
- the animals received one of the following immunizations: (1) no immunization; (2) DC2.4-mCYP-GFP; or (3) MOG 35-55 -pulsed DC2.4- mCYP-GFP.
- spinal cords were stained with Luxol Fast Blue for the analysis of demyelination and inflammation.
- Our data showed that immunization with the MOG 35-55 - pulsed DC2.4-mCYP-GFP but not the parental DC2.4-mCYP-GFP significantly ameliorated the paralytic disease. See, FIG. 9B.
- FIG. 10 shows the disease course in C57BL/6 mice immunized with MOG 35-55 emulsified in CFA to induce EAE.
- the animals received either no treatment (filled triangles) or MOG 35-55 -pulsed engineered mDC2.4-CYP cells.
- animals also received intra-peritoneal injection of an anti-CD25 monoclonal antibody (clone PC61) to deplete Foxp3 + Treg cells (open circles).
- the mAb was administered one day before and then every four days after EAE induction until the end of the experiment.
- immune regulation which is augmented by 1 ⁇ -hydroxylase- overexpressing DCs, may predominantly function in peripheral lymphoid tissues but not in CNS.
- calcitriol impairs CNS homing of CD4 + T cells by suppressing expression of a CNS-homing receptor, CXCR3.
- AST is a logical strategy to achieve this goal.
- a significant AST-associated obstacle is the instability of ex vivo generated therapeutic cellular agents in an in vivo pro-inflammatory environment in human MS patients.
- An example of such cellular agents is ex vivo induced myelin-specific Treg cells (iTreg). It has been shown that such myelin-specific iTreg cells can be adoptively transferred to enhance myelin-specific immune regulation in vivo.
- TolDCs ex vivo generated tolerogenic DCs
- MS patients are deficient in Treg cells.
- Viglietta et al. J. Exp. Med., 199, 971-979
- Matarese et al.. Proc. Natl. Acad. Sci. USA, 2005, 102:5150-5155
- Carbone ef al. Nat. Med., 2014, 20:69-74.
- the cells and methods herein disclosed provide investigative tools for elucidating the mechanisms underlying the disease suppression.
- the engineered DCs augmented apoptosis of CD4 + T cells, induced IL-10 + Treg cells and promoted immune deviation, suggesting that disease suppression, mediated by the engineered DCs, required Treg cells.
- VDR vitamin D receptor
- the vitamin D and/or calcitriol supplementation may not be able to produce a Treg-inducing calcitriol concentration in the peripheral lymphoid tissues.
- the highest possible systemic calcitriol dose which can be created by vitamin D and/or calcitriol supplementation, has to be lower than the toxicity-limiting dose and may not be sufficient to induce a strong immunoregulatory effect in the peripheral lymphoid tissues.
- a supra-physiological (therapeutic) concentration of calcitriol has been shown, in certain contexts, to be necessary for inducing Treg cells.
- the presently disclosed lct-hydroxylase- overexpressing DCs can de novo synthesize a focal Treg-inducing calcitriol concentration and at the same time prevent toxicity associated with a high systemic calcitriol concentration.
- vitamin D supplementation is important to maintain a sufficient serum level of 25[OH]D that is the substrate for 1 ⁇ -hydroxylase and is therefore necessary for 1 ⁇ -hydroxylase-overexpressing DCs to function properly.
- 25[OH]D deficiency is common among MS patients, vitamin D or 25[OH]D supplementation should be considered as an adjuvant therapy accompanying the 1 ⁇ - hydroxylase-overexpressing DC-based therapy.
- the findings presented herein suggest that the engineered DCs disclosed herein are a promising therapy for MS with an acceptable safety profile.
- the engineered DCs may help determine potential mechanisms underlying the disease suppression by this approach.
- the cells, compositions, and methods of the present application can provide a promising therapeutic agent for immune-mediated diseases, such as multiple sclerosis.
- All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and materials in connection with which the publications are cited.
Abstract
Selon un aspect, l'invention concerne des cellules dendritiques modifiées comprenant un polynucléotide hétérologue qui code pour une protéine 1α-hydroxylase. Dans certains modes de réalisation, la 1α-hydroxylase est l'élément 1 de la sous-famille B de la famille 27 du cytochrome P450 humain (CYP27B1). Selon un autre aspect, l'invention concerne des méthodes de traitement d'un sujet souffrant d'une maladie à médiation immunitaire, comprenant l'administration des cellules dendritiques modifiées.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662346416P | 2016-06-06 | 2016-06-06 | |
US62/346,416 | 2016-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017214190A1 true WO2017214190A1 (fr) | 2017-12-14 |
Family
ID=60579034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/036210 WO2017214190A1 (fr) | 2016-06-06 | 2017-06-06 | Cellules dendritiques modifiées exprimant la 1a-hydroxylase et utilisations associées pour le traitement de maladies à médiation immunitaire |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017214190A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019241479A1 (fr) * | 2018-06-14 | 2019-12-19 | Loma Linda University | Cellules souches hématopoïétiques modifiées pour le traitement de la leucémie myéloïde aiguë |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274359B1 (en) * | 1997-07-10 | 2001-08-14 | Kyowa Hakko Kogyo Co., Ltd. | 25-hydroxyvitamin D3-1α-hydroxylase and DNA encoding the hydroxylase |
US20100273748A1 (en) * | 2006-09-08 | 2010-10-28 | The Regents Of The University Of California | Antimicrobial therapy |
US8530153B1 (en) * | 2010-03-10 | 2013-09-10 | Technologiy Transfer Office, University of Manitoba | Lentiviral transduced dendritic cells for RNAi |
US20140141005A1 (en) * | 2012-02-14 | 2014-05-22 | Loma Linda University | Agents and method for treating inflammation-related conditions and diseases |
WO2016130845A1 (fr) * | 2015-02-11 | 2016-08-18 | Loma Linda University | Procédé d'utilisation de cellules dendritiques modifiées pour induire des cellules t régulatrices migrant dans l'intestin et traiter une inflammation intestinale |
-
2017
- 2017-06-06 WO PCT/US2017/036210 patent/WO2017214190A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274359B1 (en) * | 1997-07-10 | 2001-08-14 | Kyowa Hakko Kogyo Co., Ltd. | 25-hydroxyvitamin D3-1α-hydroxylase and DNA encoding the hydroxylase |
US20100273748A1 (en) * | 2006-09-08 | 2010-10-28 | The Regents Of The University Of California | Antimicrobial therapy |
US8530153B1 (en) * | 2010-03-10 | 2013-09-10 | Technologiy Transfer Office, University of Manitoba | Lentiviral transduced dendritic cells for RNAi |
US20140141005A1 (en) * | 2012-02-14 | 2014-05-22 | Loma Linda University | Agents and method for treating inflammation-related conditions and diseases |
WO2016130845A1 (fr) * | 2015-02-11 | 2016-08-18 | Loma Linda University | Procédé d'utilisation de cellules dendritiques modifiées pour induire des cellules t régulatrices migrant dans l'intestin et traiter une inflammation intestinale |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019241479A1 (fr) * | 2018-06-14 | 2019-12-19 | Loma Linda University | Cellules souches hématopoïétiques modifiées pour le traitement de la leucémie myéloïde aiguë |
EP3806864A4 (fr) * | 2018-06-14 | 2022-05-25 | Loma Linda University | Cellules souches hématopoïétiques modifiées pour le traitement de la leucémie myéloïde aiguë |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200069731A1 (en) | Methods and compositions of treating autoimmune diseases | |
US20200149121A1 (en) | Method for utilizing engineered dendritic cells to induce gut-homing regulatory t cells and treat gut inflammation | |
KR20230097209A (ko) | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 | |
JP5898260B2 (ja) | 併用療法におけるcd83の使用 | |
JP6894652B1 (ja) | 組織修復剤、組織修復剤の使用方法およびスクリーニング方法 | |
US9592259B2 (en) | APC-mediated tolerance induction for therapy of multiple sclerosis | |
WO2017189753A1 (fr) | Thérapie génique à base d'isl1 destinée à traiter une perte auditive | |
US20140286906A1 (en) | Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases | |
Li et al. | Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis | |
Koga et al. | IL10-and IL35-secreting MutuDC lines act in cooperation to inhibit memory T cell activation through LAG-3 expression | |
WO2017214190A1 (fr) | Cellules dendritiques modifiées exprimant la 1a-hydroxylase et utilisations associées pour le traitement de maladies à médiation immunitaire | |
RU2769474C2 (ru) | Способы лечения рассеянного склероза с использованием аутологичных т-клеток | |
WO2022054565A1 (fr) | Inhibiteur de tempête de cytokines, procédé destiné à l'utilisation d'un inhibiteur de tempête de cytokines et procédé destiné au dépistage d'inhibiteur des cytokines | |
US20230107770A1 (en) | Method of enhancing immunotherapy using er stress pathway inhibitors | |
US20220387517A1 (en) | Fibroblast therapy for inflammatory bowel disease | |
AU2020294700A1 (en) | Allogeneic T-cell-based HIV vaccine to induce cellular and humoral immunity | |
US9315558B2 (en) | Use of interleukin 10 mRNA transfected macrophages in anti-inflammatory therapies | |
Kishimoto et al. | Synergistic activity of IL-2 mutein with tolerogenic ImmTOR nanoparticles leads to massive expansion of antigen-specific Tregs and protection against autoimmune disease | |
EP3958887B1 (fr) | Procédures médicales d'induction ou de récupération de la tolérance immunitaire | |
Li et al. | Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1a-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis | |
US20210252072A1 (en) | Engineered hematopoietic stem cells for the treatment of acute myeloid leukemia | |
Duan et al. | Enhanced Immunosuppressive Capability of Mesenchymal Stem Cell-derived Small Extracellular Vesicles with High Expression of CD73 in Experimental Autoimmune Uveitis | |
WO2023201133A1 (fr) | Thérapie cellulaire pour la maladie d'alzheimer | |
WO2020123502A1 (fr) | Procédé de traitement de maladies auto-immunes et inflammatoires en utilisant des cellules b | |
JP2020508642A (ja) | 耐性を誘導するための操作された細胞 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17810885 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17810885 Country of ref document: EP Kind code of ref document: A1 |